Sage Therapeutics, INC Form 4 insider transactions
Laura Gault, Chief Medical Officer of Sage Therapeutics, was granted 24,000 restricted stock units and also increased her holdings through the employee stock purchase plan.
Sage Therapeutics' Chief Operating Officer, Christopher Benecchi, received 40,000 stock options and 20,000 restricted stock units on January 16, 2025, according to a recent SEC filing.
Form 4: Sage Therapeutics Director George Golumbeski Receives Stock Options in Lieu of Cash Retainer
Director George Golumbeski received 13,593 stock options from Sage Therapeutics in lieu of cash retainers for board service during 2025.
Director James Frates of Sage Therapeutics receives stock options in lieu of cash retainers for board service during 2025.
Gregory Shiferman, a Senior Vice President at Sage Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon the vesting of restricted stock units.
Sage Therapeutics' Chief Operating Officer, Christopher Benecchi, was granted stock options and restricted stock units as part of the company's 2024 Equity Incentive Plan.
Form 4: Sage Therapeutics Executive Gregory Shiferman Receives Stock Options and Restricted Stock Units
Gregory Shiferman, a Senior Vice President at Sage Therapeutics, was granted stock options and restricted stock units (RSUs) under the company's 2024 Equity Incentive Plan.
Sage Therapeutics CEO Barry E. Greene acquired 50,400 shares of common stock following the vesting of Performance Stock Units, while also disposing of shares to cover tax obligations.
Chief Medical Officer Laura Gault of Sage Therapeutics reports acquisition of shares through PSU vesting and disposition of shares to cover tax obligations.
CFO of Sage Therapeutics, Kimi Iguchi, reports acquisition and disposal of company stock following the vesting of performance stock units and a purchase under the employee stock purchase plan.
Anne Marie Cook, SVP, GC & Secretary of Sage Therapeutics, reports acquisition and disposal of company stock related to PSU vesting and tax withholding.
Christopher Benecchi, Chief Business Officer of Sage Therapeutics, reports the vesting of performance stock units and a disposition of shares to cover tax obligations.
Director Jeffrey Jonas of Sage Therapeutics, Inc. was granted stock options under the company's 2024 Equity Incentive Plan.
Director George Golumbeski received stock options for 12,500 shares of Sage Therapeutics, Inc., vesting in full by June 2025, according to a recent SEC filing.
Director Geno J Germano of Sage Therapeutics, Inc. was granted stock options for 12,500 shares on June 10, 2024, according to a Form 4 filing.
Director James M Frates received stock options from Sage Therapeutics under the company's 2024 Equity Incentive Plan.
Director Michael Cola of Sage Therapeutics, Inc. received a stock option award on June 10, 2024, under the company's 2024 Equity Incentive Plan.
Director Elizabeth Barrett of Sage Therapeutics received a stock option award for 12,500 shares on June 10, 2024, according to a Form 4 filing.
Director Jessica Federer of Sage Therapeutics was granted stock options under the company's 2024 Equity Incentive Plan.